Provexis Regulatory News (PXS)

16 Nov 2007 07:00

Provexis PLC15 November 2007 For release at 07.00 16 November 2007 PROVEXIS plc ("Provexis" or the "Company") EXCLUSIVE FRUITFLOW(R) TECHNOLOGY ASSESSMENT AGREEMENT WITH THE COCA-COLA COMPANY Provexis plc (PXS.L), which discovers, develops and licensesscientifically-proven functional food, medical food and dietary supplementtechnologies, announces the signing of a 12 month exclusive technologyassessment agreement for its patented Fruitflow(R) anti-thrombotic technologywith The Coca-Cola Company. The exclusivity agreement covers all beverages, with the exception ofmini-drinks. During the assessment period both parties will carry out aprogramme of work including consumer testing, commercial assessment andfinalising regulatory approval in a range of territories. Subject to positiveresults in these areas, the parties intend to proceed to a licensing agreementduring the period of exclusivity. There are four sectors in which Provexis is seeking major partnerships, namely,food and dairy, beverages, products for deep vein thrombosis, and dietarysupplements and medical products. The Company has an existing collaborationagreement with Unilever for certain formats within the food and dairy sectors. -ends- For further information please contact: Stephen Moon, Chief ExecutiveProvexis plc Tel: 01753 752290 Tom Griffiths/Alasdair Younie Tel: 020 7012 2000Arbuthnot Securities Chris SteeleAdventis Financial PR Tel: 020 7034 4759 This information is provided by RNS The company news service from the London Stock Exchange